問題 › 営業サイクルが長すぎる › 教育・研修事業者
長期化の主因は、社内担当者が投資家から必要とされる11.52 m USDの受講者数について承認を得られず、0.17 m USDのebitdaを支援コストで失う点にあります。 教育・研修事業者では、14.4 %と71 %の数値が鍵となります。13.44 m usdの売上達成に6,720件の受講が必要ですが、増分支援コストで0.17 m usdのebitdaが失われます。一般的な問題と実際に直面している問題では、最初の対応が異なります。
長期化の主因は、社内担当者が投資家から必要とされる11.52 m USDの受講者数について承認を得られず、0.17 m USDのebitdaを支援コストで失う点にあります。 教育・研修事業者では、14.4 %と71 %の数値が鍵となります。13.44 m usdの売上達成に6,720件の受講が必要ですが、増分支援コストで0.17 m usdのebitdaが失われます。一般的な問題と実際に直面している問題では、最初の対応が異なります。
サイクルが長くなるのは、初期の関心後に停滞するためです。社内担当者が、投資家に対して受講者数の予測と講師稼働率を説明しなければならず、投資家は議論に参加していないため学習者獲得単価のみを見るからです。
短縮するには、完了率向上と混合コホート経済に関する具体的な比較を担当者に提供し、5,760件から6,720件への移行をマージン低下なしに正当化できるようにします。
もう一つの原因は、支出を承認する権限を持たない研修担当者のみと接することです。これにより、投資家が14.4 %または18.3 %の指標を審査する段階で未追跡の承認ループが生じます。
この3つが揃うと特徴的です。1つだけでは別のことを示すことが多いです。
✓ 複数のコホートで受講者数の進捗が同じパイプライン段階で止まる
✓ 71 %完了率に基づく売上予測が同じ案件で後ろ倒しになる
✓ 落札できなかった案件の多くが他社選定ではなく「決定なし」で終わる
通常、事態を悪化させる対応です。 フォローアップの電話を増やすことです。これでは担当者に圧力がかかるだけで、投資家審査に必要な学習者獲得単価や稼働率に関する新しいデータは提供できません。
It is for you if you run or finance an education and training provider and deals consistently stall at the same stage. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 教育・研修事業者. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Brightsel Learning Group, a sample company profile used for testing rather than a customer — 11.52 m USD revenue from 5,760 enrolments.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Monetise the existing 48 contracts by adding regulatory add-ons delivered at the physical sites to lift ACV 25–30 % and protect margin.
| Investment required | 0.35–0.45 m USD (within the stated 0.85 m USD FY2026 cap) |
| Expected return | Base case incremental EBITDA of 0.45–0.55 m USD on 0.40 m USD investment yields 1.1–1.4× payback within 18 months; upside case reaches 1.8× if 5 new contracts are added by Month 24. |
| Revenue, year 1 | 12.4–12.7 m USD |
| Revenue, year 2 | 13.3–14.0 m USD |
| Revenue, year 3 | 14.5–15.5 m USD |
| Exit criteria | Strategy abandoned if, by Month 12, fewer than 50 % of the 48 contracts have renewed at the 25 % premium OR if instructor utilisation falls below 65 % for two consecutive quarters, signalling demand or capacity failure. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Go-to-Market & Commercial Strategy, one of 29 engagements the platform runs. For 教育・研修事業者 it works through 14.4 %, 71 %, 18.3 % and 312 USD, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 完全なレポートはこちらをご覧ください if you would rather see the depth first.
最も停滞している段階を見つけ、そこでバイヤーが何をしなければならないかを特定します。ほぼ常に社内承認であり、解決策は説得ではなく資料です。
最後の段階を短縮するだけで、サイクルの前半で時間がかかっている停滞には影響しません。また、待てば値引きされるとバイヤーに学習させます。
違います。案件規模と勝率が正当化できる場合は問題ではありません。キャッシュコンバージョン期間を超える場合に問題となり、それは営業ではなく資金調達の制約です。
Materially, yes. To reach 13.44 m usd revenue requires 6,720 enrolments yet incremental support costs erase 0.17 m usd of ebitda — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are 14.4 %, 71 %, 18.3 %, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on 14.4 % and 71 %. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית